Cargando…
盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015183/ https://www.ncbi.nlm.nih.gov/pubmed/26706949 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04 |
_version_ | 1783334353737089024 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects. To explore the efficacy and side effects of icotinib hydrochloride in the treatment of the advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation and wild-type. METHODS: Patients with advanced NSCLC who were treated with icotinib hydrochloride in Beijing Chest Hospital were retrospective analyzed from March 2009 to December 2014. RESULTS: The clinical data of 124 patients (99 with EGFR mutation and 25 with wild type) with advanced NSCLC were enrolled in this study. The patients' overall objective response rate (ORR) was 51.6 % and the disease control rate (DCR) was 79.8%; The patients with EGFR mutation, ORR was 63.6%, DCR was 93.9%. The ORR was 4.0% and the DCR was 24.0% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 10.5 months and 1.0 month in wild-type patients. The major adverse events were mild skin rash (30.6%) and diarrhea (16.1%). CONCLUSION: Monotherapy with icotinib hydrochloride is effective and tolerable for the advanced NSCLC EGFR mutation patients. |
format | Online Article Text |
id | pubmed-6015183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-60151832018-07-06 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects. To explore the efficacy and side effects of icotinib hydrochloride in the treatment of the advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation and wild-type. METHODS: Patients with advanced NSCLC who were treated with icotinib hydrochloride in Beijing Chest Hospital were retrospective analyzed from March 2009 to December 2014. RESULTS: The clinical data of 124 patients (99 with EGFR mutation and 25 with wild type) with advanced NSCLC were enrolled in this study. The patients' overall objective response rate (ORR) was 51.6 % and the disease control rate (DCR) was 79.8%; The patients with EGFR mutation, ORR was 63.6%, DCR was 93.9%. The ORR was 4.0% and the DCR was 24.0% in the wild-type patients. Median progression-free survival (PFS) with icotinib treatment in EGFR mutation patients was 10.5 months and 1.0 month in wild-type patients. The major adverse events were mild skin rash (30.6%) and diarrhea (16.1%). CONCLUSION: Monotherapy with icotinib hydrochloride is effective and tolerable for the advanced NSCLC EGFR mutation patients. 中国肺癌杂志编辑部 2015-12-20 /pmc/articles/PMC6015183/ /pubmed/26706949 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04 Text en 版权所有©《中国肺癌杂志》编辑部2015 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 |
title | 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 |
title_full | 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 |
title_fullStr | 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 |
title_full_unstemmed | 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 |
title_short | 盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察 |
title_sort | 盐酸埃克替尼治疗egfr突变状态明确的晚期非小细胞肺癌的临床观察 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015183/ https://www.ncbi.nlm.nih.gov/pubmed/26706949 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04 |
work_keys_str_mv | AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá AT yánsuānāikètìnízhìliáoegfrtūbiànzhuàngtàimíngquèdewǎnqīfēixiǎoxìbāofèiáidelínchuángguānchá |